TABLE 1.
Baseline characteristics and clinical outcomes of menopausal women with menopause hormone therapy.
| ID | Author and Year | Control | Treatment | Duration of study (month) | Evaluated Outcomes | ||||
|---|---|---|---|---|---|---|---|---|---|
| Intervention | n | Age (year, Mean ± SD) | Intervention | n | Age (year, Mean ± SD) | ||||
| 1 | Abbas et al. (2004) | Placebo | 29 | 56 ± 2 | 0.625 mg/day CEE (Oral) | 29 | 56 ± 2 | 3 | HDL-C |
| Placebo | 29 | 56 ± 2 | Estradiol 100 mcg/day (Transdermal) | 29 | 56 ± 2 | ||||
| 2 | Demirol et al. (2007) | Placebo | 27 | 47 ± 0.6 | 0.625 mg/d CET(Oral) | 28 | 48 ± 0.6 | 6 | Lp(a) |
| Placebo | 27 | 47 ± 0.6 | 2.5 mg/d Tibolone(Oral) | 28 | 46 ± 3 | 6 | Lp(a) | ||
| 3 | Binder et al. (1996) | Placebo | 17 | 67 ± 4 | 0.625 mg/day CEE + 5 mg MPA(Oral) | 15 | 66 ± 3 | 11 | TC TG HDL LDL |
| 4 | Bukowska et al. (2005) | Placebo | 16 | 52.2 ± 3.9 | 17 beta-estradiol (Transdermal) at increasing-decreasing doses (25, 50, 75, and 50 ug/d) + oralprogesterone 50 to 100 mg | 24 | 52.4 ± 4.8 | 3 | TG HDL Lp(a) |
| Placebo | 16 | 52.2 ± 3.9 | estradiol valerate 1mg + estriol 2 mg + levonorgestrel 0.25 mg | 21 | 52.3 ± 3.3 | 3 | |||
| 5 | Bunyavejchevin and Limpaphayom. (2001) | Placebo | 26 | 53.7 ± 4.6 | 2 mg/day 17 beta-estradiol + 1 mg NETA(Oral) | 27 | 53.4 ± 5.2 | 12 | TC TG HDL LDL |
| 6 | Casanova et al. (2009) | 3 mg/day 17β-E2 (intranasal route) +200 mg micronized P (vaginal route) | 21 | 51.2 ± 2.7 | 1 mg/day E2 + 2 mg/daydrospirenone (Oral) | 22 | 51.2 ± 2.7 | 2 | TC TG HDL LDL |
| 7 | Casanova et al. (2015a, 2015b) | 1.5 mg/day 17β-estradiol gel (percutaneous route or nasal route) +200 mg micronized progesterone (vaginal) | 51 | 51 ± 3 | 1 mg/day E2 + 2 mg/day drospirenone (Oral) | 50 | 51 ± 3 | 3 | TC TG HDL LDL |
| 8 | Castelo-Branco (1999) | Placebo | 35 | 49.9 ± 3.3 | 0.625 mg/day CEE + 2.5 mg/day medroxyprogesterone/day(Oral) | 35 | 49.0 ± 3.4 | 24 | TC TG HDL LDL |
| Placebo | 35 | 49.9 ± 3.3 | 2.5 mg/day tibolone | 35 | 52.1 ± 3.8 | ||||
| 9 | Castelo-Branco (2007) | 350 ug/day 17β-estradiol +50 ug/day norethisterone (Intranasal sprays) | 94 | 55 ± 6 | 2 mg/day 17β-estradiol + 1 mg/dayNETA(Oral) | 80 | 55 ± 6 | 12 | TC TG HDL LDL |
| 350 ug/day 17β-estradiol +175 ug/day norethisterone (Intranasal sprays) | 80 | 56 ± 5 | 2 mg/day 17β-estradiol + 1 mg/dayNETA(Oral) | 80 | 55 ± 6 | ||||
| 350 ug/day 17β-estradiol +550 ug/day norethisterone (Intranasal sprays) | 79 | 56 ± 6 | 2 mg/day 17β-estradiol + 1 mg/dayNETA(Oral) | 80 | 55 ± 6 | ||||
| 10 | Cayan et al. (2011) | No treatment | 27 | 52.3 ± 4.79 | 0.625 mg/day CEE + 5 mg/day MPA(Oral) | 26 | 50.5 ± 3.4 | 1 | TC HDL LDL TG |
| No treatment | 27 | 52.3 ± 4.79 | 2.5 mg/day tibolone | 32 | 51.5 ± 4.1 | ||||
| 11 | Cheng et al. (1993) | Placebo | 50 | 55.9 ± 5.0 | 2 mg/2 week nylestriol(Oral) | 136 | 54.4 ± 5.7 | 36 | TC TG HDL LDL |
| Placebo | 50 | 55.9 ± 5.0 | 1 mg/2 week nylestriol(Oral) | 97 | 54.8 ± 5.2 | ||||
| 12 | Christodoulakos et al. (2006) | No HRT | 76 | 56.3 ± 6.8 | 0.625 mg/day CEE + 5 mg/day MPA(Oral) | 110 | 53.7 ± 4.2 | 6 | TC TG HDL LDL |
| No HRT | 76 | 56.3 ± 6.8 | 2 mg/day of 17β-estradiol + 1 mg/day NETA(Oral) | 76 | 54.8 ± 4.4 | ||||
| No HRT | 76 | 56.3 ± 6.8 | 1 mg/day of 17β-estradiol + 0.5 mg/day NETA(Oral) | 103 | 56.1 ± 5.1 | ||||
| No HRT | 76 | 56.3 ± 6.8 | tibolone 2.5 mg | 154 | 55.1 ± 4.3 | ||||
| 13 | Haines et al. (1996) | Placebo | 45 | 43.4 ± 5.4 | 2 mg/d estradiol (Oral) | 46 | 43.8 ± 4.5 | 6 | TC TG HDL LDL Lp(a) |
| 14 | Conard et al. (1995) | Placebo | 19 | 51.1 ± 0.9 | 1 mg/day E2 + 2.5 mg nomegestrolacetate(Oral) | 19 | 52.8 ± 1.0 | 3 | TC TG HDL LDL Lp(a) |
| Placebo | 19 | 51.1 ± 0.9 | 1.5 mg/day E2 + 3.75 mg nomegestrolacetate(Oral) | 19 | 51.5 ± 0.9 | ||||
| 15 | de Kraker et al. (2004) | 1 mg/day micronised 17β-oestradiol +5 mg dydrogesterone(Oral) | 180 | 54.9 ± 5.1 | 0.625 mg/day conjugated equine oestrogens +5 mg medroxyprogesterone acetate (Oral) | 182 | 55.1 ± 5.1 | 12 | TC TG LDL |
| 16 | Faguer de Moustier et al. (1989) | 1.5–3 mg/day of E2 (Percutaneous) | 16 | / | 2 mg/day micronized E2(Oral) | 16 | / | 2 | TC TG HDL LDL |
| 17 | Draper et al. (1996) | Placebo | 64 | 53.6 ± 3.4 | 0.625 mg/day CEE(Oral) | 64 | 53.2 ± 3.3 | 2 | TC LDL HDL |
| 18 | Duvernoy et al. (2002) | Placebo | 9 | 62 ± 11 | 10 ug/day ethinyl estradiol + 1 mg/day norethindrone acetate(Oral) | 9 | 62 ± 11 | 3 | TC TG HDL LDL |
| 19 | Espeland et al. (1998) | Placebo | 72 | 55.8 ± 4.2 | 0.625 mg/day CEE(Oral) | 74 | 55.8 ± 4.2 | 36 | Lp(a) |
| Placebo | 72 | 55.8 ± 4.2 | 0.625 mg/day CEE(Oral) + 2.5 mg MPA(Oral) | 74 | 55.8 ± 4.2 | ||||
| Placebo | 72 | 55.8 ± 4.2 | 0.625 mg/day CEE(Oral) + 10 mg MPA (days 1–12, Oral) | 73 | 55.8 ± 4.2 | ||||
| Placebo | 72 | 55.8 ± 4.2 | 0.625 mg/day CEE(Oral) + 200 mg micronized progesterone (Oral ,days 1–12) | 73 | 55.8 ± 4.2 | ||||
| 20 | Farish et al. (1999) | 2.5 mg/day tibolone | 43 | 53 ± 7 | 0.625 mg/day CEE + 0.15 mg norgestrel(Oral) | 40 | 52 ± 8 | 18 | TC TG HDL LDL Lp(a) |
| 21 | Farish et al. (1996) | oral oestradiol (2 mg/ day) | 36 | 46 + 7 | oral oestradiol (2 mg/day) + norethisterone (1 mg/day) | 31 | 45 ± 6 | 12 | TC TG HDL LDL Lp(a) |
| 22 | Fernandes et al. (2008) | Placebo | 24 | 52.5 ± 4.8 | 2 mg/day micronized estradiol(Oral) | 25 | 51.6 ± 3.4 | 6 | TC TG HDL LDL |
| Placebo | 24 | 52.5 ± 4.8 | 2 mg/day micronized estradiol and 1 mg/day norethisterone(Oral) | 28 | 52.1 ± 3.7 | ||||
| 23 | Perrone et al. (1996) | No treatment | 14 | 51.8 ± 4.3 | 0.625 mg/day CEE(Oral) + 10 mg MPA (days 1–12, Oral) | 14 | 51.0 ± 4.1 | 6 | TC TG HDL LDL |
| No treatment | 14 | 51.8 ± 4.3 | 50 µg estradiol (transdermal) + 10 mg MPA (days 1–112, Oral) | 14 | 52.7 ± 3.5 | ||||
| 24 | Graser et al. (2001) | Placebo | 40 | 55 ± 5 | 2 mg/day estradiol valerate + 3 mg/day dienogest(Oral) | 43 | 55 ± 6 | 6 | TC TG HDL LDL |
| 25 | Heikkinen et al. (1997) | Placebo | 95 | 52.5 ± 0.22 | 2 mg/dayEstradiol valerate + 1 mg cyproterone acetate(Oral) | 65 | 52.9 ± 0.29 | 36 | TC TG HDL LDL |
| 26 | Teede et al. (2001) | Placebo | 30 | 60 ± 1 | 2 mg/day oestradiol anhydrous (oral) + 1 mg/day norethisterone acetate (oral) | 29 | 62 ± 2 | 24 | TC TG HDL LDL Lp(a) |
| 27 | Hemelaar et al. (2003) | Placebo | 49 | 55.0 ± 4.7 | 50 µg 17β-estradiol (transdermal) | 33 | 55.5 ± 4.8 | 17 | TC TG HDL LDL Lp(a) |
| Placebo | 49 | 55.0 ± 4.7 | 1 mg 17β-estradiol (oral) | 37 | 54.4 ± 4.3 | ||||
| Placebo | 49 | 55.0 ± 4.7 | 1 mg 17β-estradiol (oral) + 25 µg gestodene | 33 | 53.4 ± 4.2 | ||||
| 28 | Hemelaar et al. (2006) | 175 ug/day 17β-estradiol +275 ug/dayNET (Intranasal spray) | 116 | 56.8 ± 5.6 | 1 mg/day 17β-estradiol + 0.5 mg/day NETA(Oral) | 117 | 54.9 ± 4.5 | 24 | TC TG LDL Lp(a) HDL |
| 29 | Gregersen et al. (2019) | Placebo | 69 | 55.0 ± 5.2 | 2 mg/day estradiol and 1 mg/day NETA(Oral) | 71 | 55.5 ± 6.8 | 24 | TC TG HDL LDL Lp(a) |
| 30 | Conard et al. (1997) | Placebo | 16 | 54 ± 5 | 2 mg/day micronized E2(Oral) | 20 | 52 ± 4 | 6 | TC TG HDL LDL Lp(a) |
| 31 | Jirapinyo et al. (2003) | Placebo | 60 | 54.6 ± 4.4 | 2 mg/day E2 + 1 mg/dayNETA(Oral) | 60 | 54.0 ± 4.3 | 12 | TC TG HDL LDL |
| 32 | Stevenson et al. (2004) | Placebo | 27 | 56.3 ± 1.2 | 0.05 mg/dayoestradiol (transdermal) + 0.125 mg/day norethisterone acetatepatches | 28 | 59.8 ± 0.8 | 6 | TC HDL LDL |
| 33 | Koh et al. (2003) | Placebo | 26 | 60 ± 1 | 0.625 mg/day CEE + 100 mg /day MP | 53 | 59 ± 1 | 2 | TC TG HDL LDL |
| Placebo | 26 | 60 ± 1 | 2.5 mg/day tibolone | 53 | 59 ± 1 | ||||
| 34 | Koh et al. (2004) | 100 mgMP/day + 0.3 mg/day CEE(Oral) | 57 | 57 ± 1 | 100 mg MP/day + 0.625 mg/day CEE(Oral) | 57 | 57 ± 1 | 2 | TC TG HDL LDL |
| 35 | Koh et al. (2005) | 2.5 mg/day tibolone | 41 | 59.4 + 1.0 | 100 mgMP/day + 0.3 mg/day CEE(Oral) | 41 | 59.4 + 1.0 | 2 | TC TG HDL LDL |
| 36 | Labos et al. (2013) | No treatment | 36 | 50.56 ± 5.798 | 1 mg/day 17β-estradiol + 0.5 mg/day norethisterone acetate(Oral) | 26 | 51.50 ± 4.123 | 12 | TC TG HDL LDL |
| 37 | Lahdenperä et al. (1996) | 0.05 mg/day 17-beta-estradiol (Transdermal) +10 mg medroxyprogesterone acetate(Oral) | 41 | 52.6 ± 2.0 | 2 mg/day 17-beta-estradiol and 1 mg/day norethisterone acetate (Oral) | 36 | 52.3 ± 2.0 | 12 | TC TG HDL LDL |
| 38 | Lewis-Barned et al. (1999) | Placebo | 16 | 52 ± 3 | 2 mg/day 17β-estradiol + 1 mg norethisterone (Oral) | 16 | 52 ± 3 | — | — |
| 39 | Luyer et al. (2001) | Placebo | 12 | 65.3 ± 8.0 | 0.625 mg /day CEE(Oral) | 13 | 68.5 ± 7.0 | 3 | TC TG HDL LDL |
| 40 | Davidson et al. (2000) | No treatment | 83 | 58.7 ± 5.2 | 2 mg/day Oestradiol + 1 mg norethisterine (Day 17–28) | 23 | 58.2 ± 6.7 | — | — |
| No treatment | 83 | 58.7 ± 5.2 | 2 mg/day Oestradiol + 700 ug norethisterine | 22 | 58.2 ± 6.7 | ||||
| No treatment | 83 | 58.7 ± 5.2 | 50 ug/day Oestradiol + 170 ug norethisterine (Day 14–28) | 33 | 58.2 ± 6.7 | ||||
| No treatment | 83 | 58.7 ± 5.2 | 50 ug/day Oestradiol + 100 mg testoserone | 34 | 51.7 ± 3.8 | ||||
| 41 | Terauchi et al. (2012) | Placebo | 67 | 53.0 ± 4.1 | 0.5 mg/day mE2 | 72 | 52.9 ± 3.6 | 2 | TC TG HDL LDL |
| Placebo | 67 | 53.0 ± 4.1 | 1.0 mg/day mE2 | 71 | 52.8 ± 4.6 | ||||
| 42 | Mendoza et al. (2002) | 2.5 mg/day tibolone | 55 | 50.7 ± 4.2 | 50 ug/day 17β- oestradiol + 0.25 mg NETA(Transdermal) | 55 | 49.6 ± 3.6 | 12 | TC TG HDL LDL |
| 2.5 mg/day tibolone | 55 | 50.7 ± 4.2 | 50 g/day 17-oestradiol (transdermal) + 200 mg progesterone 2/w (oral) | 55 | 50.6 ± 4.2 | ||||
| 43 | Meschia et al. (1998) | Placebo | 41 | 53 ± 4.2 | 50 µg 17β-estradiol (transdermal) + 10 mg MPA (days 1–12) | 60 | 52 ± 4.3 | 3 | TC TG HDL LDL Lp(a) |
| Placebo | 41 | 53 ± 4.2 | 0.625 mg/day CEE(Oral) + 10 mg MPA (days 1–12) | 60 | 51 ± 4.4 | ||||
| 44 | Seed et al. (2000) | Placebo | 66 | 57.1 ± 6.8 | 1 mg/day 17β-estradiol | 67 | 58.6 ± 5.6 | 6 | TC TG HDL LDL Lp(a) |
| Placebo | 66 | 57.1 ± 6.8 | 1 mg/day 17β-estradiol + 0.25 mg norethisterone acetate | 68 | 58.1 ± 5.8 | ||||
| Placebo | 66 | 57.1 ± 6.8 | 1 mg/day 17β-estradiol + 0. 5 mg norethisterone acetate | 63 | 57.7 ± 6.2 | ||||
| 45 | Mijatovic et al. (1999) | No treatment | 13 | 53.2 ± 3.5 | 1 mg/day micronized E2 (Oral) + 5 mg/day or 10 mg/day dydrogesterone | 14 | 51.4 ± 4.0 | 15 | Lp(a) |
| 46 | Milner et al. (1996) | Placebo | 50 | 55.6 ± 0.61 | 0.625 mg/day CEE + 0.15 mg norgestrel (Oral) | 32 | 52.4 ± 0.74 | 24 | TC TG HDL LDL Lp(a) |
| Placebo | 50 | 55.6 ± 0.61 | 2.5 mg/day tibolone | 31 | 53.6 ± 0.77 | ||||
| 47 | Munk-Jensen et al. (1994) | Placebo | 38 | / | Combination: 2 mg/day of 17β-estradiol + 1 mg/day NETA (Oral) | 37 | / | 24 | TC TG HDL LDL |
| Placebo | 38 | / | Sequential: 2 mg/day of 17β-estradiol + 1 mg NETA (Oral) | 38 | / | ||||
| 48 | Oral and Ozbaşar (2003) | Placebo | 28 | 65 ± 1.9 | 0.625 mg/day CEE + 5 mg/day MPA(Oral) | 30 | 64 ± 2.1 | 18 | TC TG HDL LDL |
| 49 | Pan et al. (2002) | 2.5 mg/day tibolone | 17 | 51.2 ± 4.3 | 0.625 mg/day CEE (Oral) | 23 | 52.5 ± 3.4 | 6 | TC TG HDL LDL |
| 50 | Kotecha et al. (2020) | placebo | 34 | 60.5 (57.1, 65.4) | 2 mg/day 17β-estradiol + 1 mg/day norethisterone acetate (Oral) | 34 | 60.7 (57.3, 62.8) | 24 | TC TG HDL LDL Lp(a) |
| placebo | 34 | 60.5 (57.1, 65.4) | 2.5 mg tibolone | 33 | 61.0 (57.7, 65.0) | 24 | TC TG HDL LDL Lp(a) | ||
| 51 | Villa et al. (2011) | placebo | 20 | 51.9 ± 2.4 | 1 mg/day E2dose (oral) + drospirenone | 20 | 52 ± 3.3 | 6 | TC TG HDL LDL Lp(a) |
| 52 | Samantray KV et al. (1994) | placebo | 15 | 48.4 ± 2.6 | 0 625 mg/day CEE (Oral) | 15 | 47.7 ± 3.1 | 3 | TC TG HDL LDL |
| placebo | 15 | 48.4 ± 2.6 | 0.625 mg/day CEE + 2.5 mg/day MPA (Oral) | 15 | 49.3 ± 2.8 | ||||
| 53 | Samsioe et al. (2002) | placebo | 40 | 56.2 ± 4.6 | 1 mg/day E2 + 0.25 mg/day NETA (Oral) | 40 | 55.6 ± 4.3 | 12 | TC TG HDL LDL Lp(a) |
| placebo | 40 | 56.2 ± 4.6 | 1 mg/day E2 + 0.5 mg/day NETA (Oral) | 40 | 56.7 ± 5.1 | ||||
| 54 | Sanada et al. (2003) | No treatment | 15 | 54.8 ± 4.8 | 0.625 mg/day CEE + 2.5 mg MPA (Oral) | 18 | 55.1 ± 5.2 | 3 | TC TG HDL LDL |
| No treatment | 15 | 54.8 ± 4.8 | 0.3 mg/day CEE + 2.5 mg MPA (Oral) | 18 | 55.3 ± 5.3 | ||||
| 55 | Sendag et al. (2002) | 0.05 mg/day 17β estradiol +0.25 mg norethindrone acetate (Transdermal) | 42 | 47.36 ± 3.8 | 0.625 CEE mg/day + 10 MPA mg (Oral) | 42 | 47.57 ± 3.9 | 6 | TC TG HDL LDL |
| 56 | Siseles et al. (1995) | 2.5 mg/day tibolone | 13 | / | 5 mg MPA + 0.625 mg/day CE(Oral) | 11 | / | 6 | TC TG HDL LDL |
| 6 | TC TG HDL LDL | ||||||||
| 57 | Stadberg et al. (1996) | 1 mg E2/day + 0.25 mg/day NETA(Oral) | 19 | 58.5 | 2 mg E2/day + 1 mg/day NETA(Oral) | 21 | 58.5 | 12 | TC TG HDL LDL Lp(a) |
| 1 mg E2/day + 0.5 mg/day NETA(Oral) | 20 | 58.5 | 2 mg E2/day + 1 mg/day NETA(Oral) | 21 | 58.5 | ||||
| 58 | Taechakraichana et al. (2000) | 30 ug/day ethinyl E2 + 150 ug desogestre(Oral) | 40 | 51.0 ± 0.6 | 0.625 mg/day CEE + 5 mg medrogestone(Oral) | 40 | 52.3 ± 0.6 | 12 | TC TG HDL LDL |
| 59 | Taskinen et al. (1996) | 50 μg/day 17β-estradiol(Transdermal) +10 mg MPA | 57 | 52.3 ± 2.3 | 2 mg/day 17β-estradiol + 1 mg NETA(Oral) | 55 | 52.5 ± 2.5 | 12 | TC TG HDL LDL |
| 60 | Tilly-Kiesi et al. (1996) | 50 μg/day 17β-estradiol(Transdermal) +10 mg MPA | 38 | 52.6 ± 2.0 | 2 mg/day 17β-estradiol and 1 mg/day norethisterone acetate(Oral) | 37 | 52.3 ± 2.1 | 12 | TC TG HDL LDL |
| 61 | Vaisar et al. (2021) | Placebo | 56 | 50.7 (48,53) | 100 ug/day estradiol (Transdermal) | 45 | 51.1 (48,53) | 6 | TC TG HDL LD |
| 62 | Tuck et al. (1997) | Placebo | 15 | 54.5 ± 6.1 | 0.625 mg/day CEE(Oral) | 15 | 54.5 ± 6.1 | 6 | TC TG HDL LDL |
| 63 | Ulloa et al. (2002) | Placebo | 11 | 55.1 ± 1.2 | 0.625 mg/dayCEE + 5 mg MPA(Oral) | 17 | 53.8 ± 1.0 | 2 | TC TG HDL LDL |
| 64 | Villa et al. (2008) | Placebo | 16 | 53.54 + 3.7 | 1 mg/day E2 + 10 mg MPA(Oral) | 16 | 52.44 + 3.2 | 3 | TC TG HDL LDL |
| Placebo | 16 | 53.54 + 3.7 | 2 mg/day E2 + 10 mg MPA(Oral) | 16 | 54.5 + 4.1 | ||||
| 65 | Wakatsuki and Sagara (1996) | 0.625 mg/day CEE(Oral) | 28 | / | 0.625 mg/day CEE(Oral) + 2.5 mg MPA(Oral) | 21 | / | 3 | TC TG HDL LDL |
| 0.625 mg/day CEE(Oral) | 28 | / | 0.625 mg/day CEE(Oral) + 5 mg MPA(Oral) | 21 | / | ||||
| 66 | Wakatsuki et al. (2002) | No treatment | 12 | 53.4 ± 7.3 | 0.625 mg/day CEE(Oral) | 16 | 52.4 ± 3.3 | 3 | TC TG HDL LDL |
| No treatment | 12 | 53.4 ± 7.3 | 50 μg/day 17β -estradiol(Transdermal) | 16 | 54.7 ± 5.9 | ||||
| 67 | Wakatsuki et al. (2003) | No treatment | 14 | 53.4 ± 7.3 | 0.3125 mg/day CEE(Oral) | 17 | 54.8 ± 6.8 | 3 | TC TG HDL LDL |
| No treatment | 14 | 53.4 ± 7.3 | 0.625 mg/day CEE(Oral) | 15 | 54.8 ± 7.3 | ||||
| 68 | Miller et al.,1995 | placebo | 174 | / | 0.625 mg/dayCEE(Oral) | 175 | / | 36 | TC TG HDL LDL |
| placebo | 174 | / | 0.625 mg/dayCEE(Oral) + cyclic 10 mg/day MPA (12 d/month) | 174 | / | ||||
| placebo | 174 | / | 0.625 mg/dayCEE(Oral) + 2.5 mg/day MPA | 174 | / | ||||
| placebo | 174 | / | 0.625 mg/dayCEE(Oral) + cyclic 200 mg/day micronized progesterone (12d/month) | 178 | / | ||||
| 69 | Xue et al. (2016) | 0.3 mg/day CEE + 100 mg MP(Oral) | 35 | 53.7 ± 4.2 | 0.625 mg/day CEE + 100 mg MP(Oral) | 37 | 53.1 ± 3.1 | 12 | TC TG HDL LDL |
| 0.3 mg/day CEE + 100 mg MP(Oral) | 35 | 53.7 ± 4.2 | 0.625 mg/day CEE + 10 mg dydrogesterone(Oral) | 35 | 53.4 ± 4.5 | ||||
| 70 | Yang et al. (1999) | 2.5 mg/day tibolone | 20 | 50.90 ± 3.42 | 0.625 mg/day CE + 5 mg MPA(Oral) | 20 | 51.80 ± 3.09 | 6 | TC TG HDL LDL |
| 71 | Yang et al. (2002) | placebo | 18 | 50.5 ± 2.79 | 2 mg/day 17β-estradiol + 1 mg/day norethisterone acetate(Oral) | 22 | 51.5 ± 3.70 | 4 | TC TG HDL LDL |
| 72 | Zegura et al. (2006) | Placebo | 30 | 55.4 ± 6.4 | 2 mg/day E2(Oral) | 20 | 49.2 ± 4.0 | 6 | TC TG LDL Lp(a) HDL |
| Placebo | 30 | 55.4 ± 6.4 | 50 μg/day E2(Transdermal) | 21 | 47.8 ± 4.1 | ||||
| Placebo | 30 | 55.4 ± 6.4 | 2 mg/day E2 + 1 mg/day NETA(Oral) | 31 | 55.1 ± 5.3 | ||||
| 73 | Ziaei et al. (2010) | Placebo | 50 | 52.52 ± 4.06 | 0.625 mg/day CEE + 2.5 mg MPA(Oral) | 50 | 51.58 ± 2.82 | 6 | TG HDL |
| Placebo | 50 | 52.52 ± 4.06 | 2.5 mg/day tibolone | 50 | 51.78 ± 3.29 | ||||
Abbreviation: CEE, conjugated equine estrogen; MPA, medroxyprogesterone acetate; E2, Estradiol; SD, Standard Deviation